Selected Publications

Mircetic, J.*, Camgöz, A., Abohawya, M., Ding, L., Dietzel, J., Tobar, S.G., Paszkowski‐Rogacz, M., Seidlitz, T., Schmäche, T., Mehnert, M. et al. CRISPR/Cas9 Screen in Gastric Cancer Patient‐Derived Organoids Reveals KDM1A‐NDRG1 Axis as a Targetable Vulnerability. Small Methods, 2201605 (2023). 10.1002/smtd.202201605.

Sayed, S., Sidorova, O.Alexandra., Hennig, A., Augsburg, M., Vesga, C.P.C., Abohawya, M., Schmitt, L.Theo., Surun, D., Stange, D.E., Mircetic, J., et al. Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing. Cancer Res. 82, 3002–3015 (2022). 10.1158/0008-5472.can-21-2519.

Mircetic, J., Dietrich, A., Paszkowski-Rogacz, M., Krause, M. & Buchholz, F. Development of a genetic sensor that eliminates p53 deficient cells. Nat. Commun. 8, 1463 (2017). 10.1038/s41467-017-01688-w.

Mircetic, J., Steinebrunner, I., Ding, L., Fei, J.-F., Bogdanova, A., Drechsel, D. & Buchholz, F. Purified Cas9 Fusion Proteins for Advanced Genome Manipulation. Small Methods 471, 1652–1658 (2017). 10.1002/smtd.201600052.

Broghammer, F., Korovina, I., Gouda, M., Celotti, M., van Es, J., Lange, I., Brunner, C., Mircetic, J., Poppes, R.P., Gires, O., et al. Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome. Mol Cancer 23, 39 (2024). 10.1186/s12943-024-01954-8.